Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech Limited reported audited standalone financial results for FY2025-26. Revenue from operations declined to Rs. 1,05,507.10 lakhs from Rs. 1,20,008.69 lakhs in the previous year, representing approximately 12% revenue decline. Profit after tax (PAT) fell to Rs. 26,326.67 lakhs from Rs. 37,296.44 lakhs, marking about 29% decline year-on-year. The company recorded an exceptional item of Rs. 327.54 lakhs due to statutory impact of new labour codes. The Board recommended a dividend of Rs. 7.55 per equity share. Statutory auditors BSR & Co. LLP issued an unmodified (clean) opinion on both standalone and consolidated financial results. The company also announced appointment of new Internal Auditor (Manubhai & Shah LLP), Cost Auditor (Dalwadi & Associates), and Mrs. Ekta Gupta as Additional Independent Director.
The significant decline in revenue and PAT for FY26 indicates challenging business conditions. However, the clean audit opinion and dividend recommendation suggest the company maintains financial integrity and continues rewarding shareholders. The stock may face short-term pressure due to earnings decline.